Summary
The aim of laboratory screening in Phase I is to exclude subjects with subclinical illness, who might be at increased risk in the study, and who might also adversely influence interpretation of the results.
A new method for laboratory screening, based on Bayesian probability theory, is proposed, which consists of:
-
1.
Drawing up a list of diseases to be excluded.
-
2.
Defining for each disease, the maximum acceptable risk that an included subject could be affected by it.
-
3.
Identifying one test for each disease.
-
4.
Using a contingency table to calculate the specificity of the test and integrating the estimated prevalence of the disease from epidemiological data.
-
5.
Applying the percentage obtained by the calculation of specificity to the previously determined distribution of values in the volunteer population to identify the threshold value for inclusion.
Use of this deductive method in screening volunteers for Phase I trials affords increased security of selection, while reducing the number of non-pertinent exclusions because of laboratory findings.
Similar content being viewed by others
References
Grasbeck R, Siest G, Wilding GZ, Whitehead TP (1978) IFCC Committee on Standards. Expert panel on the theory of reference values. Clin Chem Acta 87: 461–469
Joubert P, Rivera-Calimlim L, Lasagna L (1975) The normal volunteer in clinical investigation: How rigid should selection criteria be? Clin Pharmacol Ther 17: 253–257
Joubert P, Pannall P (1976) The selection of healthy volonteers for clinical investigation: the case for volunteer pools. Cur Med Res Opin 4: 192–196
Schoen I, Broown SH (1970) Judgment based on 95% confidence limits: A statistical dilemma involving multitest screening and proficiency testing of multiple specimens. Am J Clin Pathol 53: 190–193
Schrogie JJ, Hensley MJ, Diogore CH, Harris S (1977) Evaluation of the prison inmate as a subject in drug assessment. Clin Pharmacol Ther 21: 1–7
Thompson LW, Brunelle RL, Enas GG, Simpson PJ (1987) Routine Laboratory Tests in Clinical Trials: Interpretation of Results. J Clin Res Drug Develop 119: 1–95
Weinstein MC, Fineberg HV (1980) Clinical decision analysis. Saunders, Philadelphia, pp 75
Woodward W (1979) Informed consent of volunteers: a direct measurement of comprehension and retention of information. Clin Res 27: 248–249
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sibille, M., Vital Durand, D. Laboratory screening method for selection of healthy volunteers. Eur J Clin Pharmacol 39, 475–479 (1990). https://doi.org/10.1007/BF00280939
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00280939